Solabegron is primarily investigated for its potential therapeutic applications in treating overactive bladder (OAB) syndrome. It acts as a selective beta-3 adrenergic receptor agonist, which helps relax the bladder muscle, increasing its storage capacity and reducing the frequency of involuntary contractions. This makes it a promising option for alleviating symptoms such as urinary urgency, incontinence, and frequent urination. Additionally, research has explored its potential use in managing irritable bowel syndrome (IBS) due to its ability to modulate smooth muscle activity in the gastrointestinal tract. Its mechanism of action offers a targeted approach with fewer side effects compared to traditional treatments, making it a valuable candidate for improving quality of life in patients with these conditions.